MRK 241213 104.00P (MRK241213P104000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

MRK241213P104000

Watchlist

2.41
+1.26+109.57%

15min DelayClose Dec 10 16:00 ET

2.50High2.11Low

Intraday

5D
Daily

News

BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $121
Moomoo News56minutes ago · Ratings
Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?
Yahoo Finance23:47 ET
BofA Restarts Coverage of 11 Large-cap Biopharmas
Seeking Alpha17:01 ET
Market Falls Wednesday, but Googles Chip Impresses | WST
Kevin Travers16:19 ET
EMD Serono Appoints Miguel Fernández Alcalde to Lead North American Healthcare Business
Businesswire13:40 ET
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga12:35 ET

Comments

籠的傳人288

23 hours ago

Rolling sell put csp contracts for mrk.

Alot of times you would hear people say, roll down (csp) or roll up (covered call) their option contracts. Basically rolling your contract is cancel the first contract (cut loss) and open a new second contract. But the second contract must cover the loss of the first contract or minimum must break even or take a small loss.
On oct 10/24, open 2 x mrk contracts at 109.29c, strike at 105 and premium of 192 x 2 (35 dte). On nov 5/24, i closed 2 x contracts a...

This_Guy

Dec 8 17:14

$Merck & Co (MRK.US)$
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Positive
100% complete response rate achieved at 1.75 mg/kg dose level
High overall response rate across all dosage groups (93.3-100%)
Strong 12-month duration of response at 93.5%
Successfully established recommended Phase 3 dose
Negative
58% of patients exp...

Stock_Drift

Dec 8 15:26

$Merck & Co (MRK.US)$

Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Bellaah

Dec 5 13:16

$Merck & Co (MRK.US)$ 110

Stock_Drift

Dec 5 06:01

$Merck & Co (MRK.US)$